Derivati USA: CME-CBOT-NYMEX-ICE T-Bronx5Y-10Y-Bund .. il ritorno del figliol prodigo (vm18) (1 Viewer)

f4f

翠鸟科
goood morning bbbanda


d'accordo con Gipa, consolida in alto
ma richiede, a mio parere, un giretto in basso per prendere forza, mica tatnto, un 1% a 38700 e lì aspiett ....


gastro
mi servono un pò più di parametri ....
durata del movimento, obiettivo e max rintracciamento 'senza negare'
alla vola ci penza Fleu :p
 

frank73

OPTION TRADER
Purtroppo ho avuto pesantemente ragione,dico purtroppo perche ho alleggerito troppo ma mi tengo le mie put strette strette su dicembre.
Vi ricordate la mia sicurezza sulla possibile discesa dopo il NAPM di fine settembre,il market sui payrolls di venerdi immagginavo strappasse gli stop e venerdi mattina ho dovuto alleggerire.
Il 118.60 di venerdi era il famoso ultimo caccia stop di cui parlavo da giorni.
Al momento sta scendendo veloce opzione che avevo scartato dopo le 2 settimane di discesa lenta.
Al momento credo che 117 sia un buon prezzo per le opzioni novembre e li si fermeranno ma non so se riusciro ad incrementare prima perche domani e dopodomani c'è minute e beige book,per non parlare dell'international trade e venerdi retails sales michigan ed import export.
Insomma questi fanno sul serio la calmierata alla curva usa la vedevo lontano un miglio e t-bond -0.36.
Ciao
 

gipa69

collegio dei patafisici
frank73 ha scritto:
Al momento la correzione su sp500 è un puro miraggio

Consolida alto mantenendo quindi la forza del trend ben impostata.
La debolezza dello yen si conferma soprattuto contro dollaro in fase di recupero contro quasi tutte le monete.
Prosegue la debolezza del bond post payroll
Deboli anche le commodity.. debolezza legata soprattuto alla forza del dollaro.
Continua lo scenario positivo anche se tutto deve mantenersi così per continuare.....
Elevato rischio di posizione....
 

gipa69

collegio dei patafisici
Fed's Fisher: Will do what it takes to control inflation
Tue Oct 10, 2006 1:07pm ET
By Veronica Brown and Antonina Vorobyova

LONDON, Oct 10 (Reuters) - Dallas Federal Reserve Bank President Richard Fisher said on Tuesday he is comfortable with U.S. interest rates at current levels but stressed that they could rise further if inflation, already on the high side, does not come under control.

"I'm very comfortable with the policy of where we are today," Fisher said in a question and answer session in London after delivering a speech on globalisation.


But "if it appears that we haven't done enough to quell inflation, then obviously I would be in favour of additional measures," he said, adding: "The current rate of inflation is too high."

The Fed's favoured index of non-food, non-energy inflation rose 2.5 percent in the 12 months to August, the biggest gain since April 1995 and well above the 1 to 2 percent range many officials have said they would like to see.

While month-to-month changes in core inflation have moderated after a surprise acceleration earlier this year, on a year-on-year basis underlying inflation continues to mount.

Fisher, a non-voting member of the Fed's rate-setting Open Market Committee, said that the Fed's inflation-fighting credentials are not in doubt, something that financial markets appreciate.

"I do not believe that there is any doubt in the market as to our reseolve for dealing with inflation and keeping it under control," Fisher said.

"I will do everything to make sure inflation doesn't raise its ugly head."

The federal funds rate has been on hold at 5.25 percent for two months now after the Fed broke a string of 17 consecutive rate increases earlier this summer.

Fisher downplayed concerns over the U.S. housing market correction, which he said was one of the most over-analyzed and over-anticipated in history. He recognized that the sector has gone through a rocky patch recently and has contributed to the slowing of overall economic growth. But he warned against becoming fixated about one sector of the economy, adding that housing and the auto sector apart, the United States is firing on all cylinders.

That belief appears to be attracting converts in financial markets. In recent sessions traders have pushed up the dollar, stocks and bond yields and pared back expectations that the Fed might cut rates in the early part of next year to cushion the economic slowdown.


In his speech Fisher said that international policymakers must take into account data on the working of the global economy as they try to set domestic monetary policy.

Spotty data on many emerging economies -- or no data at all -- showed the complexity of the task that policy-makers face, though they had to consider whatever was available, Fisher said.

"The bottom line is that we have a great deal of accounting and analytical work left to do as we seek to refine our ability to make monetary policy in a globalised world," Fisher said.

Fisher said that, for example, it was hard to properly gauge capacity utilisation rates in any one country without taking into consideration rates in the global economy.

"I believe it is insufficient to think in terms of domestic resource utilisation alone in our globalised world: we need to be looking at capacity and slack at the global level," Fisher said: "But how do we measure these things?"

In many emerging economies, the data needed to make such calculations "simply don't exist", he said.

He noted that in China, despite the fact that it is in the midst of a fixed-asset investment boom, "there are no official estimates of its capital stock which is a basic component in measuring an output gap".

In China's case, despite its growing economic might, information on capacity utilisation or unemployment figures that might shed some insight on how near to capacity its economy was operating "are spotty at best, released erratically and difficult to interpret", Fisher said.
 

gipa69

collegio dei patafisici
Alcoa 3Q Profit Jumps 86 Percent
Tuesday October 10, 4:49 pm ET
Alcoa 3Q Profit Jumps 86 Percent on Aerospace, Transporation Demand


PITTSBURGH (AP) -- Aluminum producer Alcoa Inc. on Tuesday said third-quarter profit skyrocketed 86 percent as demand from the aerospace and commercial transportation sectors continued to drive up results despite lower aluminum prices.

But its results were well below Wall Street expectations, and its shares fell in trading after the bell.

Net income rose to $537 million, or 61 cents per share, in the three months ended Sept. 30 from $289 million, or 33 cents per share, a year ago.

Revenue jumped 19 percent to $7.6 billion from $6.4 billion. But sales decreased 2 percent from the second quarter, however, mainly due to lower prices and seasonal market changes.

Analysts surveyed by Thomson Financial forecast third-quarter profit of 79 cents per share, on average, and sales of $7.68 billion. A year ago, the company earned 33 cents per share.

Its shares rose 30 cents to close at $28.29 in trading on the New Yoirk Stock Exchange. The report was released after the bell, and its shares fell 11 cents to $28.08.
 

gipa69

collegio dei patafisici
AP
Genentech Profit Surges 58 Percent
Tuesday October 10, 4:48 pm ET
By Paul Elias, AP Biotechnology Writer
Genentech Profit Rises 58 Percent on Strong Drugs Sales, Introduction of Eye Disorder Treatment


SAN FRANCISCO (AP) -- Third-quarter profit surged 58 percent for biotechnology company Genentech Inc. behind strong drugs sales and the introduction of a new treatment for an eye disorder, the company announced Tuesday.

South San Francisco-based Genentech reported a profit of $568 million, or 53 cents a share, for the quarter, compared to $359 million, or 33 cents a share, for the same period last year.

If not for special expenses, including employee stock options, the company said it would have earned $637 million, or 59 cents per share. On that basis, the company exceeded Wall Street analysts' expectations by eight cents a share, according to Thomson Financial.

Genentech said it expected earnings per share to grow by 65 percent to 70 percent for the full year.

The company's revenue rose 36 percent to $2.39 billion for the quarter, largely because of the continued popularity of Genentech's pricey cancer-fighting drugs. Sales of the non-Hodgkin's lymphoma treatment Rituxan rose 12 percent to $509 million for the quarter while sales for its colon cancer staple Avastin shot up 34 percent to $435 million.

Lucentis, the company's newest drug that treats the eye disease macular degeneration had sales of $153 million in the quarter. The Food and Drug Administration approved Lucentis on June 30.

"We are encouraged by strong initial physician acceptance of Lucentis," said Genentech chief executive Arthur Levinson. "The rapid adoption of the recently available Lucentis product reflects the fact that wet age-related macular degeneration is a key unmet medical need."

The results were released after the market closed. The company's shares fell 68 cents to close at $85.60, and tumbled $1.60 or 1.87 percent to $84 in after hours trading.
 

Users who are viewing this thread

Alto